The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind <i>Candida albicans</i> abundance and macrophage polarizationOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the pancreatic (islet) inflammation that occurs after islet cell transplantation (ICT) in type 2 diabetes (T2D), and whether chitooligosaccharides (COS) could reduce that inflammation. The researchers focused on how ICT affects the gut mycobiome (fungal community) and how resulting changes in fungal abundance influence macrophage polarization. They tested whether COS, previously shown to modulate immunity and gut microecology, could correct these changes and relieve islet inflammation.
Who was studied?
Fecal samples from an ICT patient population undergoing islet cell transplantation for diabetes were analyzed using 18S rDNA gene sequencing to profile gut fungal communities. The findings were then validated using human flora-associated T2D (HMA-T2D) mouse models, in which mice were colonized with human-derived gut microbiota. No specific patient sample size is given in the abstract.
What were the most important findings?
ICT significantly decreased the alpha diversity of gut fungi, altered fungal community structure, and increased the abundance of Candida albicans. This Candida albicans expansion promoted M1 (pro-inflammatory) macrophage polarization, which drove islet inflammation. Oligosaccharides were screened for the ability to regulate macrophage polarization and inhibit Candida albicans growth, and COS was validated in HMA-T2D mice as able to alleviate this inflammation and regulate gut microbiota.
What are the greatest implications of this study?
The findings identify gut fungal dysbiosis, specifically Candida albicans overgrowth, as a contributor to macrophage-driven islet inflammation after transplantation, a mechanism that could undermine islet graft survival. This suggests the gut mycobiome is a relevant target for improving outcomes in islet cell transplantation for diabetes. Chitooligosaccharides emerge as a candidate intervention that may protect transplanted islets by correcting fungal dysbiosis and shifting macrophage polarization away from a pro-inflammatory state.